🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Amyotrophic Lateral Sclerosis

Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging NCT07202494n/a1 site📍 Marseille Assistance Publique Hopitaux De Marseille · Tests: Imaging Techniques (MRI 3T & 7T, Functional, Structural, and Metabolic Imaging) Examining Interactions Between PALS and Caregivers NCT06819124NA1 site📍 University Park Penn State University · Tests: Structured Communicative Interaction, Unstructured communicative interaction Intestinal Microbiome Transplant in ALS NCT07017946Phase 1, Phase 21 site📍 Durham Duke University · Tests: MTP-101C Biomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis NCT06318598n/a3 sites📍 Milan📍 Milan📍 Torino Istituto Auxologico Italiano GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices NCT07127172NA2 sites📍 London📍 Newcastle upon Tyne Neuralink Corp · Tests: N1 Implant, R1 Robot Video-Based Proprioceptive Exercise Program in ALS NCT07292545NA1 site📍 Mersin Tarsus University · Tests: video based exercise Biomarkers of Synaptic Damage in Multiple Sclerosis NCT03217396n/a1 site📍 Pozzilli Neuromed IRCCS · Tests: lumbar puncture EIM Via the Myolex mScan as an ALS Biomarker NCT06491732n/a6 sites📍 Phoenix📍 Boston📍 Boston Beth Israel Deaconess Medical Center · Tests: Electrical Impedance Myography A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation NCT06556394Phase 13 sites📍 Beijing📍 Chengdu📍 Hangzhou Ractigen Therapeutics. · Tests: RAG-17, Placebo Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications NCT06266403NA1 site📍 University Park Penn State University · Tests: Structured Communicative Interaction, Clear Speech, Unstructured communicative interaction, Clear Speech Structured Com… Retinal Imaging in Neurodegenerative Disease NCT03233646n/a1 site📍 Durham Duke University · Tests: Retinal and Choroidal Imaging Dysphagia, QoL and Attitudes Towards PEG in ALS Patients NCT05336760n/a1 site📍 Ljubljana University Rehabilitation Institute, Republic of Slovenia · Tests: Iowa Oral Performance Instrument (IOPI), Mann Assessment of Swallowing Ability (MASA), Fiberoptic Endoscopic Evaluation… Structural and Functional Networks in ALS: An Insight Into Pseudobulbar Affect NCT06396260NA1 site📍 Aalborg Aalborg University Hospital · Tests: Diffusion Kurtosis Imaging (DKI), Resting State Magnetoencephalography Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders NCT05116943n/a1 site📍 Jacksonville Mayo Clinic Identification of Early Markers for ALS NCT07213440NA1 site📍 Tours Institut National de la Santé Et de la Recherche Médicale, … · Tests: lumbar puncture Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS NCT07322003Phase 356 sites📍 Phoenix📍 San Francisco📍 Aurora Prilenia · Tests: Pridopidine, Placebo Needs of ALS Patients With C9orf72 Mutation and Their Caregivers NCT07302321n/a3 sites📍 Milan📍 Milan📍 Pavia Istituto Auxologico Italiano · Tests: Survey for ALS patients, Survey for Caregivers Quantitative and Repetitive TMS in ALS - Recruiting for Stage 2 NCT05983211NA1 site📍 Toronto Sunnybrook Health Sciences Centre · Tests: Repetitive Transcranial Magnetic Stimulation Creation of a Clinical Database for the Study of Phenotypic Variability in Motor Neuron Diseases NCT06318585n/a1 site📍 Milan Istituto Auxologico Italiano Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS NCT06126315Phase 2, Phase 319 sites📍 Sydney📍 Brescia📍 Bergamo Mario Negri Institute for Pharmacological Research · Tests: Acetyl-l-carnitine, Placebo At-home Treatment With Cortico-spinal tDCS for Amyotrophic Lateral Sclerosis NCT07006571NA1 site📍 Trieste University of Trieste · Tests: Real tDCS, Sham tDCS Proteinopathies Expression in Skin of Neurodegenerative Disorders NCT06528964n/a1 site📍 San Luis Potosí City Universidad Autonoma de San Luis Potosí · Tests: Immunohistochemistry and immunofluorescence Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis NCT07023835Phase 249 sites📍 La Jolla📍 Orange📍 San Francisco Zydus Therapeutics Inc. · Tests: 50 mg Usnoflast, 75 mg Usnoflast, Placebo Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS) NCT03366506n/a1 site📍 Jerusalem Hadassah Medical Organization · Tests: Observation Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients NCT03127267Phase 356 sites📍 Birmingham📍 Los Angeles📍 Lexington AB Science · Tests: Masitinib (6.0), Riluzole, Placebo, Masitinib (4.5) Reinnervation and Neuromuscular Transmission in ALS NCT06219759n/a1 site📍 Aarhus University of Aarhus · Tests: Observational study Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease NCT05136222NA13 sites📍 Adelaide📍 Brisbane📍 Canberra University of Melbourne · Tests: Intervention polysomnography, Sham polysomnography Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS) NCT04454892n/a1 site📍 Beijing Peking University Third Hospital · Tests: Amyotrophic lateral sclerosis Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT) NCT07521930NA1 site📍 Baltimore Johns Hopkins University · Tests: INTENT Neural Interface System Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers NCT05395624Phase 1, Phase 23 sites📍 San Francisco📍 Stanford📍 Jacksonville Ashvattha Therapeutics, Inc. · Tests: 18F-OP-801
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy